Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.
Investigators conducted a case-control study of 3030 pancreatic cancer patients in an attempt to confirm which genes might render patients susceptible to pancreatic cancer.
Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.
Adding midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy provides significant survival benefit for patients with AML and a FLT3 mutation.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Presence of JAK2 mutation and leukocytosis are strong predictors for thromboembolic events in patients with essential thrombocythemia (ET).
Genetic signatures similar to BRCA1/BRCA2 mutations could make PARP inhibition a treatment option for some breast cancers.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
Researchers say it's likely that all the major genetic mutations related to colorectal cancer have been discovered.
The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.
Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.
Palbociclib Plus Fulvestrant Provides Significant Benefit in Hormone Receptor-Positive Metastatic Breast CancerJune 03, 2016
ESR1 mutations detected in plasma circulating tumor DNA were identified in a high percentage of patients with hormone receptor-positive metastatic breast cancer, confirming an important role in endocrine resistance, according to an analysis of data from the phase 3 PALOMA-3 reported at the 2016 ASCO Annual Meeting.
ESR1 Mutations Predict Worse Outcome in HR-positive Metastatic Breast Cancer Treated with Aromatase InhibitorsJune 03, 2016
The presence of circulating ESR1 somatic mutations at disease progression in patients with HR-positive metastatic breast cancer treated with first-line AIs represent a strong and independent poor prognostic value for overall survival but no predictive value, a study presented at the 2016 ASCO Annual Meeting has found.
Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.
The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.
Disparities in BRCA1/2 testing in black and white women is attributable to differences in physician recommendations, according to a recent study.
Progression-free and Overall Survival Better With Mutations Affecting DNA Repair Genes in Ovarian CancerApril 08, 2016
Women with advanced ovarian cancer who had mutations affecting DNA repair genes had longer progression-free and overall survival than women without the mutations.
Germline mutations to the RECQL gene were identified in 0.5% of patients with familial breast cancer in a Chinese population.
A pattern of mutations across several key cancer genes was found in patients with throat cancer who were exposed to both human papillomavirus (HPV) and tobacco smoke.
Among 1915 patients with ovarian cancer, almost 1 in 5 had inherited mutations in genes associated with risk of ovarian cancer. Furthermore, a total of 11 genes are now suspected of causing hereditary ovarian cancer.
Two distinct causes of HER2 activation in lung cancer were demonstrated in a recent study. These findings imply that HER2-positive lung cancer may need different targeted therapies to combat these related but possibly distinct diseases.
The researchers found that nearly one fifth of women with ovarian cancer carried mutations in genes that were associated with ovarian cancer risk beyond the BRCA1 and BRCA2 genes.
The evolution of drug resistance in a patient with lung cancer was demonstrated in a recent case. In the case, molecular analysis of a metastatic lesion revealed resistance to a third targeted therapy; however, the new mutation restored tumor response to the first targeted therapy used.
Comprehensive genomic screening may be warranted for all pediatric patients with cancer, not just those with a family history of cancer, according to results of a detailed analysis of germline mutations in cancer predisposition genes.
Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.
Most patients with NSCLC that has metastasized to the brain have a dire prognosis. However, researchers have identified a subset of those patients who have a rare genetic mutation and are living significantly longer than patients without the mutation.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
- Acupuncture Eases Some Self-Reported Symptoms of Cancer, Cancer Treatments
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|